Progyny Beats Q2 Estimates, Raises Full-Year Outlook; CEO and Chairman Adopt 10b5-1 Plans
PGNY sits 63% above its 52-week low of $16.1.
Summary
Progyny posted better-than-expected Q2 results and raised its full-year outlook, but the CEO and Chairman adopted 10b5-1 plans to sell up to 3.27 million shares.
Key Events · Earnings and Guidance · PGNY
-
Q2 Earnings Beat
Revenue of $350.5M (+5% YoY) and net income of $28.1M (+64% YoY) exceeded consensus. Gross margin expanded 180 bps to 25.5%.
-
Full-Year Guidance Raised
Management increased its 2026 outlook, citing strong client demand and operational efficiencies.
-
CEO and Chairman Adopt 10b5-1 Plans
CEO Pete Anevski adopted a plan to sell up to 1.97M shares; Executive Chairman David Schlanger adopted a plan for up to 1.3M shares. Both plans run through October 2027.
-
Aggressive Share Buybacks Continue
Repurchased 6.7M shares YTD for $148M at an average price of $22.08. $168.5M remains under the May 2026 $200M authorization.
Analysis · PGNY · Industrial Applications And Services
Progyny delivered a strong Q2, with revenue up 5% to $350.5M and net income surging 64% to $28.1M, driven by margin expansion and lower stock-based compensation. Management raised full-year guidance, signaling confidence in the demand pipeline. However, the filing also reveals that the CEO and Executive Chairman adopted 10b5-1 trading plans covering up to 3.27 million shares combined — a notable overhang even if sales are pre-planned. The company continues to aggressively buy back stock, with $148M repurchased year-to-date, but the insider selling plans may temper enthusiasm around the earnings beat.
At the time of this filing, PGNY was trading at $26.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $16.10 to $33.07. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.